IRBM
MIT-LS 2014 Pitch Presentation - March 31, 2014

The privately owned IRBM Group consists of: IRBM; IRBM PROMIDIS; Advent; CNCCS Consortium.

The group operates within a 70,000 m2 research facility located near Rome which opened in 2009 as a spin-off from the Istituto di Ricerche di Biologia Molecolare P. Angeletti S.p.a., the then Merck & Co research site.

IRBM has an impressive drug discovery track record, having delivered 25 molecules advancing into preclinical and clinical development. These include the marketed drug Isentress, the first-in-class HIV integrase inhibitor for the treatment of HIV/AIDS (awarded the Prix Galien USA 2008 Award for Best Pharmaceutical Agent), Grazoprevir a pan-genotypic HCV protease inhibitor currently in late stage clinical trials (FDA "Breakthrough Therapy Designation" for HCV interferon free therapy). The team also made key contributions to the development of Zolinza (SAHA): first-in-class HDAC inhibitor for the treatment of cancer.

IRBM currently employs 120+ scientists with extensive drug discovery experience, more than half qualified to MSc/PhD. IRBM operates a hybrid business model having proprietary drug discovery programmes and offering "one stop shop" preclinical small molecule and peptide drug discovery services. This can involve an integrated drug discovery service or any single capability ranging from target validation, assay development, HTS, small molecule and peptide optimisation, in vitro - vivo pharmacology and preclinical ADMET optimisation.

IRBM PROMIDIS has extensive translational medicine expertise in neurodegenerative diseases, including rare diseases such as Huntington's Disease and Fragile X syndrome. Promidis is the partner of choice for innovative drug discovery projects, aimed at restoring protein homeostasis, based on HT immunoassay development and screening for protein detection and quantification in cell-based and ex-vivo human application.

Advent is a GMP-accredited manufacturing facility for the production of investigational adenoviral vectors for gene therapy and/or genetic vaccination.

CNCCS is a public-private consortium (CNR, Istituto Superiore di Sanità and IRBM). It operates a central repository of organic compounds and is a National and European HTS hub.

Areas of Activity
CRO (Contract Research Organization)
Diagnostics
In vitro diagnostics
Peptides, proteins & antibodies synthesis
Pharmaceutics
Research & Development
Therapeutics

свернуть